Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 109,062

Document Document Title
WO/2015/118554A1
The disclosure herein provides 1-carbamoyloxyethyl 5-(1,2-dithiolan-3-yl)pentanoate derivatives of formula I, formula II and formula III. The disclosure also provides a method of synthesizing the compound of formula I, formula II and for...  
WO/2015/120317A1
New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.  
WO/2015/118026A1
The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R'" but may not be a quaternary C atom; R' is -OR1, -CONH2, -CF3, F, -OH, -NO2, -CN or -OCO...  
WO/2015/119126A1
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...  
WO/2015/118019A1
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/119111A1
The problem addressed by the present invention is to provide an anti-prion compound having high crystallinity and high crystal stability, and to provide an agent for the prevention, amelioration, and treatment of prion disease. The prese...  
WO/2015/120280A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patien...  
WO/2015/120203A1
The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin.  
WO/2015/120434A1
Described herein are nieihods for the prevention of neurodegeneratiori and the treatment of ncwodegenerati ve disease (Including amyotrophic lateral sclerosis) ami tieurodeveiopmetifal disorders through the administration of an agent tha...  
WO/2015/120233A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.  
WO/2015/118019A9
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/120446A1
In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some...  
WO/2015/120038A1
The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-rnediated events following a brain injury or long-term neuroinflammat...  
WO/2015/118363A1
The present invention relates to a food supplement comprising L-tryptophan and vitamins from the B vitamins group, to pharmaceutical compositions containing said food supplement and to the production process of said food supplement.  
WO/2015/119998A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or am...  
WO/2015/113169A1
Provided herein are humanized antibodies or antigen-binding fragments thereof, that can bind to a cyclic peptide comprising the amino acid sequence SNK, wherein the K (Lysine) is solvent-accessible and methods of treating and/or preventi...  
WO/2015/115582A1
Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally subst...  
WO/2015/114308A1
The present invention provides the steroidal compound3-ethynyl-3- hydroxyandrostan-17-one oxime,or a pharmaceutically acceptable saltthereof,for usein treatment ofhepaticencephalopathy.  
WO/2015/115507A1
Provided is a compound represented by formula (I) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof. This compound has an excellent TRPA1 antagonistic activity, which makes it possible t...  
WO/2015/114395A9
The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an e...  
WO/2015/113452A1
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 k...  
WO/2015/115898A1
The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaeno...  
WO/2015/116492A1
The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.  
WO/2015/116663A1
The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and met...  
WO/2015/114315A1
2-Chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known ...  
WO/2015/115509A1
The purpose of the present invention is to provide a therapeutic or prophylactic agent for multiple sclerosis, which contains a non-steroid low-molecular-weight compound as an active ingredient. The present invention provides a therapeut...  
WO/2015/114660A1
The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceu...  
WO/2015/115331A1
 A humanized antibody including an H chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NOS: 1-3 and an L chain complementarity determining region comprising an amino acid sequence shown by SEQ I...  
WO/2015/113980A1
The present invention relates to compounds of formula (I), wherein A and B, X, Y, Z, and R1-R6 are as defined in the claims, for the treatment of neurological disorders.  
WO/2015/117094A1
In alternative embodiments the invention provides methods for synthesizing AB-007 (also called loxistatin, E64d, EST or ((2S,3S)-trans-epoxysuccinyl-L-leucyl-amido-3-methylbutane ethyl ester) and its acid form E64c (loxistatin acid), and...  
WO/2015/114395A1
The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an e...  
WO/2015/115673A1
The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compou...  
WO/2015/113200A1
A hydrochloric tapentadol injection and a preparation method thereof. The injection comprises an effective amount of an active ingredient of hydrochloric tapentadol salt or tapentadol alkali, a pharmaceutical carrier that is pharmaceutic...  
WO/2015/115899A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white m...  
WO/2015/115885A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white m...  
WO/2015/116060A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/115886A1
The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaeno...  
WO/2015/113451A1
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for exampl...  
WO/2015/115332A1
 A human antibody including an H chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NOS: 1-3 and an L chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NO...  
WO/2015/116923A1
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta- associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated...  
WO/2015/112369A1
Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol that in...  
WO/2015/112168A3
This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.  
WO/2015/111602A1
Provided are: a method for producing adult oligodendrocyte-type-2 astrocyte progenitor cells from proliferative oligodendrocyte-type-2 astrocyte progenitor cells; and a pharmaceutical composition having as an effectivecomponent thereof a...  
WO/2015/110271A1
The present invention relates to diazabicyclo[4.3.1 ]decane derivatives (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically a...  
WO/2015/112715A1
The present invention includes compositions and methods for treating a human subject in need of treatment for traumatic brain injury or neurological damage resulting from exposure to one or more low-energy impacts, comprising administeri...  
WO/2015/109935A1
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...  
WO/2015/113057A1
Compounds (I), processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the FP, DP, EP1, EP4, I...  
WO/2015/109666A1
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...  
WO/2015/109377A1
The present invention relates to a new efficient and industrially feasible process for the preparation of the commercial crystalline forms of donepezil hydrochloride Form I and III, with high purity and in a selective manner. This invent...  
WO/2015/110589A1
The present invention concerns the field of ion channels, and in particular relates to peptides which are suitable for use in the treatment of conditions where the L-type calcium channel (LTCC) density and function is altered. LTCCs are ...  

Matches 501 - 550 out of 109,062